IPT-based Group Intervention by Non-specialist for Improvement of Depressive Symptoms in Community Young Adults in Brazil
Major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the World Health Organization (WHO). Furthermore, it's also related to decreased quality of life and high mortality. Interpersonal psychotherapy (IPT) is a first-line treatment and can also be used for the prevention of depression. This randomized controlled clinical trial is planned to have 50 participants randomized…
Conditions studied
Depression, Interpersonal Relations
About this study
Major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the World Health Organization (WHO). Furthermore, it's also related to decreased quality of life and high mortality. Interpersonal psychotherapy (IPT) is a first-line treatment and can also be used for the prevention of depression. This randomized controlled clinical trial is planned to have 50 participants randomized between an interventional and a control group (waiting list). Our study covers young adults (18 to 24 years old) with depression. Participants will be invited by social media to undergo treatment in an IPT group. The intervention group will be separated into groups with up to 10 participants, with a weekly meeting for eight weeks. The intervention will focus on interpersonal relationships within the model of IPT and will be held by a university student and a doctor trained in IPT.
Interventions
- Behavioral: Interpersonal psychotherapy — Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
Primary outcomes
- Hospital Anxiety and Depression Scale (HADS) (Pre-treatment, Week 1 to 8)
Eligibility information
Study locations
- Clinical Hospital for Porto Alegre, Porto Alegre, Rio Grande do Sul 90035-903 Brazil
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.